The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | Why is it important to risk stratify patients in CLL?
Kostas Stamatopoulos, MD, PhD from the Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece provides an overview of chronic lymphocytic leukemia (CLL) at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY. Dr Stamatopoulos discusses the significant progress in CLL and how physicians go about stratifying patients in order allocate specific treatments to improve outcomes. He also mentions where research should be directed in the future.
